Intravitreal Avastin not associated with increased endophthalmitis risk

Intravitreal injections of bevacizumab do not pose a greater risk of endophthalmitis than intravitreal injections of ranibizumab, according to a study.In response to reports of endophthalmitis outbreaks ostensibly linked to repackaged bevacizumab, the FDA issued a draft guidance allowing the use of compounded bevacizumab with “beyond use” dates that limit use to within 5 days of repackaging.

Full Story →